Clinical Trials

Breast Neoplasms, Breast Neoplasms, Male

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

1,020 enrolled

Phase 1/2 Not yet recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07389733 2026-03-02

A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer

180 enrolled

Advanced Unresectable or Metastatic Breast Cancer of Adults

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast Cancer Metastatic

NCT07288359 2026-02-23

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04546009 2026-02-20

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

992 enrolled

Breast Neoplasms

NCT06905301 2026-02-20

IMPULSE

Recruiting

240 enrolled

Breast Neoplasms

NCT06998407 2026-02-20

AVZO-023-1001

380 enrolled

HR+/HER2- Breast Cancer

NCT02499146 2026-02-11

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Phase 1 Completed

26 enrolled 40 charts

Advanced Breast Cancer

NCT05909397 2026-02-10

VERITAC-3

59 enrolled

Breast Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT02246621 2026-02-03

MONARCH 3

493 enrolled 23 charts 1 FDA

Phase 4 Active not recruiting

Breast Neoplasms

NCT05161195 2026-02-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT01872260 2026-01-30

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

255 enrolled

Breast Neoplasms

NCT05514054 2026-01-29

EMBER-4

8,000 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT02057133 2026-01-26

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

198 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07349069 2026-01-22

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

4,800 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07340658 2026-01-14

SIE-3

300 enrolled

Breast Neoplasms

NCT03056755 2026-01-13

BYLieve

Phase 2 Completed

383 enrolled 16 charts

Phase 3 Enrolling by invitation

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT05645536 2026-01-12

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

250 enrolled

Breast Neoplasms, Neoplasms

NCT06974929 2025-12-30

A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

80 enrolled

Breast Neoplasms

NCT04735367 2025-12-09

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Completed

42 enrolled 7 charts

Phase 2 Active not recruiting

Breast Neoplasms

NCT05226871 2025-11-25

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

35 enrolled

BreastHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06086340 2025-11-18

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Completed

779 enrolled 9 charts

Breast Neoplasms, Neoplasm Metastasis

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Phase 2 Completed

327 enrolled

Breast Neoplasms

NCT02297438 2025-10-27

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Phase 3 Completed

340 enrolled 29 charts

Phase 2 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT04557449 2025-10-01

CDK4i

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT06465368 2025-10-01

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Phase 2 Completed

121 enrolled

Breast Neoplasms

NCT04191382 2025-09-18

AMEERA-4

Phase 2 Terminated

105 enrolled 16 charts

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

Breast Neoplasms

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast Neoplasms

NCT04606446 2025-08-13

KAT6

Phase 1 Recruiting

320 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05257395 2025-07-17

A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer

397 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT06570031 2025-07-02

ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer

46 enrolled

Breast Neoplasms, Neoplasm Metastasis, Recurrence

NCT03099174 2025-06-24

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

Phase 1 Completed

133 enrolled 26 charts

Breast Neoplasms, Neoplasms

NCT06555068 2025-06-22

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

528 enrolled